FindTrial
Sign In

USE OF RIFAXIMIN THERAPY IN PRIMARY PREVENTION OF HEPATORENAL SYNDROME IN CIRRHOTIC PATIENTS WITH ASCITES

USE OF RIFAXIMIN THERAPY IN PRIMARY PREVENTION OF HEPATORENAL SYNDROME IN CIRRHOTIC PATIENTS WITH ASCITES - USE OF RIFAXIMIN THERAPY IN PRIMARY PREVENTION OF HEPATORENAL SYNDROME IN CIRRHOTIC PATIENTS WITH ASCITES

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000038487
Enrollment
94
Registered
2019-11-03
Start date
2019-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Cirrhosis with ascites

Interventions

Rifaximin group ,Tab rifaximin at a dose of 550mg BD for 12 weeks and other standard treatment. Non Rifaximin group,Only standar Rx.

Sponsors

NationalAcademy of health Sciences,Bir Hospital Department Of Medicine Gastroenterology Unit
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Age of the patients to be above 18 yrs . 2.Diagnosis of liver cirrhosis and documented ascites. 3.Child-Pugh score of 7 or more

Exclusion criteria

Exclusion criteria: 1. Patients with renal impairment (serum creatinine>1.5mg/dl) 2. History of HRS, nephropathy and obstructive Uropathy 3. Recent exposure to radioactive materials and Nephrotoxic drugs 4. Sepsis 5. Hepatocellular carcinoma 6. History of allergic reaction with rifaxmin.

Design outcomes

Primary

MeasureTime frame
Occurrence of hepatorenal syndrome within 12 weeks.—

Secondary

MeasureTime frame
Change in urea and creatinine level at 4 week,8week and 12 week.—

Countries

Asia(except Japan)

Contacts

Public ContactSanjit Karki

Patan Academy of Health sciences Medicine,Gastrenterology

sanjitkarki@pahs.edu.np9841277196

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026